Skip to main content

Peter Murphy, who recovered COVID-19 and is now donating his plasma, poses for a portrait at his home June 25, 2020 in Ottawa.

Dave Chan/Dave Chan

If a second wave of COVID-19 slams into Canada in the fall, doctors are planning to have freezers full of convalescent plasma ready to deploy as part of an effort to determine, once and for all, whether the straw-coloured liquid in the blood of survivors can help save the newly infected.

More than 500 Canadians who have recovered from COVID-19 have already donated their plasma to a clinical trial that aims to enroll 1,200 coronavirus-infected patients who are sick enough to be admitted to hospital, but early enough in their illness that a stranger’s antibodies might still have time to win a fight against the virus.

Peter Murphy, a 51-year-old project manager for a steel company in Ottawa, is one of the COVID-19 survivors hoping his plasma will be an effective medicine for the coronavirus patients who come after him.

Story continues below advertisement

“Even if they can’t necessarily use my plasma to specifically save somebody, they can use it to learn,” Mr. Murphy said of researchers. “That’s fine too. This is uncharted territory.”

It’s uncharted territory in the case of COVID-19, but not in medical history. As far back as the late 1800s, doctors have been experimenting with convalescent plasma as a treatment for viral and bacterial infections, including measles, polio, mumps and Spanish influenza.

Canada begins clinical trial of experimental COVID-19 treatment using plasma from recovered individuals

NIH Director Collins optimistic on COVID-19 vaccine by year end

The concept is simple enough: Transfuse the antibody-rich plasma of patients who have recovered or “convalesced” into freshly infected people whose own immune systems haven’t had time to start pumping out antibodies. It seemed to work during the Spanish flu pandemic of 1918-1919, when some studies – although crude by today’s standards – found that convalescent plasma cut the death rate for influenza pneumonia in half.

Convalescent plasma has since been used to fight SARS, Middle East respiratory syndrome (MERS) and Ebola with hints of success, but mixed results overall.

The picture isn’t any clearer for SARS-CoV-2, the virus that causes COVID-19. The only randomized clinical trial of convalescent plasma published to date was inconclusive; it was terminated early because doctors in Wuhan, China, ran out of patients when public-health measures brought the epidemic there under control.

In the United States, more than 20,000 people have received plasma from recovered COVID-19 patients with special permission from the Food and Drug Administration (FDA), although not in a randomized clinical trial with a control group for comparison.

Data from those U.S. patients show convalescent plasma is safe for use in COVID-19, said Jeannie Callum, the director of transfusion medicine at Toronto’s Sunnybrook Health Sciences Centre. “What we don’t know is, does it really do anything?”

Story continues below advertisement

That’s what Dr. Callum, one of three co-lead researchers, is hoping to figure out through the Canadian clinical trial, known as CONCOR-1.

Now is the best time for patients who survived Canada’s first wave to donate, said Dana Devine, chief scientist for Canadian Blood Services, which is collecting plasma for use in CONCOR-1.

“Your antibody level doesn’t stay high forever,” Dr. Devine said. “We need people to come now and do these donations so that we have plasma ready for the second wave.”

As of July 2, 125 recovered patients had donated their plasma to Canadian Blood Services, some more than once. Another 38 were booked to donate soon. In Quebec, 408 convalescent plasma donors made 897 donations as of June 22, according to Héma-Québec, the province’s blood authority.

That’s more than enough plasma to satisfy the need in Canada, where the first wave has ebbed and the number of coronavirus patients in hospital has plummeted.

CONCOR-1 had randomized 44 patients as of Thursday, two-thirds of whom received convalescent plasma, the rest regular care.

Story continues below advertisement

“At the beginning, our problem was a supply problem,” said Donald Arnold, director of the McMaster Centre for Transfusion Research in Hamilton, and another of CONCOR-1′s lead researchers. “Now we’re at the stage where we’re facing demand challenges because there just aren’t enough patients that need the trial.”

However, he and Dr. Callum are confident they’ll be able to finish the trial. If the coronavirus roars back in the fall, as most infectious-disease experts predict, they intend to have plenty of antibody-rich convalescent plasma ready to thaw and use against a disease for which only a few other treatments have shown any promise.

Peter Murphy’s first plasma donation is already on ice. He made it on May 16, about two months after the day he believes he caught the coronavirus from someone who came into his office for meetings.

The virus hit him “like a ton of bricks,” Mr. Murphy said. He experienced deep fatigue, extreme joint pain and the worst digestive upset of his life. He felt near-delirious at points. He spent 32 days in quarantine at home, sustained by food and supplies dropped off by friends and neighbours, some of whom he barely knew before his wife asked for help through a street-wide e-mail list.

“This thing, amazingly, really brought our whole street together,” Mr. Murphy said. “It was one of our neighbours down the street who first saw a post about the [convalescent plasma] study and sent it to my wife. It was like, well, this is a no-brainer.”

After his first donation, a sample of Mr. Murphy’s plasma was sent to a lab to be tested for levels of neutralizing antibodies, the kind that render the virus incapable of infecting cells.

Story continues below advertisement

Mr. Murphy’s plasma got the green light. Now he intends to donate every two weeks for the rest of the year. Each time he gives, his plasma will be tested for neutralizing antibodies, making him one of the relatively few Canadians who can access regular updates on the state of his body’s defences against the coronavirus.

That said, Mr. Murphy remains on guard. He knows the scientific jury is still out on how much immunity his antibodies actually confer, and how long that immunity might last.

“There’s no sense of invincibility,” he said.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you manage your health, your finances and your family life as Canada reopens.
Visit the hub

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies